Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Aligos Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aligos Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aligos Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Aligos Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aligos Therapeutics (ALGS) has a FCF Margin % of -89.82% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aligos Therapeutics and its competitors. According to the industry distribution chart, Aligos Therapeutics ranks #632 out of 956 companies in the Biotechnology industry, placing it in the top 66.1%.
Is Aligos Therapeutics' FCF Margin % too high?
Aligos Therapeutics' current FCF Margin % is -89.82%. Based on the distribution chart, Aligos Therapeutics ranks #632 out of 956 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aligos Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' FCF Margin % compare to CRVO and PVCT?
According to the Biotechnology industry distribution chart, Aligos Therapeutics ranks #632 out of 956 companies for FCF Margin %. This places Aligos Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aligos Therapeutics and its competitors. Aligos Therapeutics's current FCF Margin % is -89.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Possible Value Trap. The stock's GF Value™ is $34.29, compared to a current price of $7.47 — trading 78.2% below its estimated fair value. The current FCF Margin % is -89.82%. Aligos Therapeutics' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current FCF Margin % is -89.82% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aligos Therapeutics (ALGS) Overvalued in 2026?
Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be undervalued.
The current stock price of $7.47 is trading 78.2% below its estimated GF Value™ of $34.29.
GuruFocus considers Aligos Therapeutics to be Possible Value Trap.
Key valuation signals for ALGS:
FCF Margin %: -89.82%
GF Value™: $34.29 vs. price of $7.47 (78.2% below fair value)
No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
41GF Score
Get the complete analysis for ALGS
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALGS has been successfully added to your 
